IN THE SPECIFICATION

Page 6, at the bottom of the page, please replace the structural formula (II) as follows:



(II)



(II)

Page 9, near the top of the page; please replace the structural formula II' as follows:



(II')



(II')

Please replace the paragraph beginning at page 11, line 12, with the following rewritten paragraph:

Particular embodiments relate to the compounds of formula III wherein R_{30}, R_{32}, R_{33}, R_{34}, Q, Z and n are as defined above; and wherein

(a) p is one;

(b) Y_1 is O, S, SO, SO_2, $N(R_6)SO_2$ or $N\text{-}R_6$; and

(c) X_2 is lower alkylene; or when n is zero, X_2 is also C_2-C_7-alkylene interrupted by O, S, SO, SO_2 or NR_6;

wherein ~~N~~$_6$ R_6 is as defined above and pharmaceutically acceptable salts thereof.

Please replace the paragraph beginning at page 18, line 4, with the following rewritten paragraph:

Examples of substituted phenyl groups as R are, e.g. 4-chlorophen-1-yl, 3,4-dichlorophen-l yl, 4-methoxyphen-l-yl, 4-methylphen-l-yl, 4-aminomethylphen-l-yl, 4-methoxyethylaminomethylphen-1-yl, 4-hydroxyethylaminomethylphen-1-yl, 4-hydroxyethyl (methyl)-aminomethylphen-1-yl, 3-aminomethylphen-1-yl, 4-N-acetylaminomethylphen-1-yl, 4-aminophen-l-yl, 3-aminophen-l-yl, 2-aminophen-l-yl, 4-phenyl-phen-l-yl, 4-(imidazol-l-yl)-phen-1-yl, 4-(imidazol-1-ylmethyl)-phen-1-yl, 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-ylmethyl)-phen-1-yl, 4-(2-methoxyethylaminomethyl)-phen-1-yl and 4-(pyrrolidin- l-ylmethyl)-phen-l-yl, 4-(2-thiophenyl)-phen-1-yl, 4-(3-thiophenyl)-phen-l-yl, ~~4-(4-methylpiperazen-1-yl-phen-1-yl)~~ 4-(4-methylpiperazin-1-yl)-phen-1-yl, and 4-(piperidinyl)-phenyl and 4(pyridinyl)-phenyl optionally substituted in the heterocyclic ring.

Please replace the paragraph beginning at page 28, line14, with the following rewritten paragraph:

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees ~~Centrigrade~~

Centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g. microanalysis and spectroscopic characteristics (e.g. MS, IR, NMR). Abbreviations used are those conventional in the art.

Page 34, please replace section for compound "30" in the table as follows:

30		89-91	0.19 (CH_2CL_2/MeOH=9:1)

Page 44, please replace section for compound "43" in the table as follows:

43		H	126-128	0.19 (CH_2CL_2/MeOH=9:1)

Page 44, please replace section for compound "45" in the table as follows:

45		H	147-149	0.24 (CH_2Cl_2/MeOH=9:1)

Page 46, please replace section for compound "63 in the table as follows:

63			~~1199-201~~ 199-201	446

Page 48, please replace section for compound "69" in the table as follows:

69		58	135-137	0.29 (CH_2Cl_2/MeOH=9:1)

Page 52, please replace section for compound "75" in the table as follows:

75		45	-	0.17 (CH_2Cl_2/MeOH=95:5)

Please replace the paragraph at page 86, line 2, middle of page, with the following rewritten paragraph:

The compounds of Table 9 are typically selective inhibitors for cathepsin L, having ~~IC_{50}S~~ IC_{50}s for cathepsin ~~S~~ L inhibition which are preferably in the range fromabout 100 to about 1 nM.